By Kyle Morris

Shares in ImmuPharma rose 11% on Thursday after the company said it received positive guidance from the U.S. Food and Drug Administration that supports an Investigational New Drug application and a phase 2/3 adaptive clinical trial of the P140 platform for patients with chronic idiopathic demyelinating polyneuropathy.

Shares at 0850 GMT were up 0.33 pence at 3.40 pence.

The company said the FDA feedback recognised that P140 is suitable to be studied in another disease indication in addition to systemic lupus erythematosus, which supports P140 across several auto-immune/inflammatory diseases.

An IND application will now be prepared for submission to the FDA.

An application for Orphan Drug status for CIDP will be also submitted in parallel to the full IND application.

Write to Kyle Morris at kyle.morris@dowjones.com

(END) Dow Jones Newswires

May 18, 2023 05:23 ET (09:23 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Immupharma.
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Immupharma.